Pharmacokinetics of Dalbavancin in Patients With Renal or Hepatic Impairment

被引:59
|
作者
Marbury, Thomas [2 ]
Dowell, James A. [1 ]
Seltzer, Elyse [1 ]
Buckwalter, Mary [1 ]
机构
[1] Vicuron, New York, NY USA
[2] Orlando Clin Res Ctr, Orlando, FL USA
来源
JOURNAL OF CLINICAL PHARMACOLOGY | 2009年 / 49卷 / 04期
关键词
Dalbavancin; pharmacokinetics; renal impairment; hepatic impairment; ONCE-WEEKLY DALBAVANCIN; CRITICALLY-ILL PATIENTS; SEMISYNTHETIC GLYCOPEPTIDE; TEICOPLANIN; LIPOGLYCOPEPTIDE; OTOTOXICITY; INFECTIONS; RATIONALE; THERAPY; SKIN;
D O I
10.1177/0091270008330162
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Three open-label studies assessed the safety, tolerability, and pharmacokinetics of intravenous dalbavancin in patients with hepatic or renal impairment, including patients with end-stage renal disease (ESRD) receiving dialysis. In each study, 4 to 10 patients with mild, moderate, or severe impairment and age-, sex-, and weight-matched controls were administered either a single dose (500 or 1000 mg) or 2 doses (1000 mg followed by 500 mg 1 week apart) of dalbavancin. Dalbavancin exposures were not increased due to mild renal impairment. The mean area under the concentration-time curve from time 0 to infinity (AUC(0-infinity)) values were approximately 50% higher in patients with moderate renal impairment or ESRD and 100% higher in patients with severe renal impairment. Dose adjustment is not considered necessary in patients with mild or moderate renal impairment or for patients with ESRD receiving hemodialysis; however, a lower dose of dalbavancin (750 mg followed 1 week later by 375 mg) may be considered for patients with severe renal impairment (creatinine clearance <30 mL/min). AUC(0-infinity) values were similar in patients with mild hepatic impairment and were about 27% to 36% lower in patients with moderate to severe hepatic impairment compared with controls. No dosage adjustment is recommended in patients with any degree of hepatic impairment. Dalbavancin was well tolerated in all impairment groups.
引用
收藏
页码:465 / 476
页数:12
相关论文
共 50 条
  • [1] Pharmacokinetics of Voxelotor in Patients With Renal and Hepatic Impairment
    Preston, Richard A.
    Marbury, Thomas
    Balaratnam, Ganesh
    Green, Michelle
    Dixon, Sandy
    Lehrer-Graiwer, Josh
    Washington, Carla
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2021, 61 (04): : 493 - 505
  • [2] The pharmacokinetics of dalbavancin in subjects with mild, moderate, or severe hepatic impairment
    J Dowell
    E Seltzer
    M Buckwalter
    T Marbury
    D Simoneau
    E Boudry
    [J]. Critical Care, 12 (Suppl 2):
  • [3] Pharmacokinetics of candesartan cilexetil in patients with renal or hepatic impairment
    deZeeuw, D
    Remuzzi, G
    Kirch, W
    [J]. JOURNAL OF HUMAN HYPERTENSION, 1997, 11 : S37 - S42
  • [4] Pharmacokinetics of Voclosporin in Renal Impairment and Hepatic Impairment
    Ling, S. Y.
    Huizinga, R. B.
    Mayo, P. R.
    Freitag, D. G.
    Aspeslet, L. J.
    Foster, R. T.
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 53 (12): : 1303 - 1312
  • [5] Asenapine Pharmacokinetics in Hepatic and Renal Impairment
    Peeters, Pierre
    Bockbrader, Howard
    Spaans, Edwin
    Dogterom, Peter
    Lasseter, Kenneth
    Marbury, Thomas
    Gibson, Gordon L.
    de Greef, Rik
    [J]. CLINICAL PHARMACOKINETICS, 2011, 50 (07) : 471 - 481
  • [6] Asenapine Pharmacokinetics in Hepatic and Renal Impairment
    Pierre Peeters
    Howard Bockbrader
    Edwin Spaans
    Peter Dogterom
    Kenneth Lasseter
    Thomas Marbury
    Gordon L. Gibson
    Rik de Greef
    [J]. Clinical Pharmacokinetics, 2011, 50 : 471 - 481
  • [7] Population pharmacokinetics (PK) of riociguat in patients (pts) with renal and hepatic impairment
    Saleh, Soundos
    Becker, Corina
    Frey, Reiner
    Mueck, Wolfgang
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [8] Effect of Renal or Hepatic Impairment on the Pharmacokinetics of Mirabegron
    James Dickinson
    Michaelene Lewand
    Taiji Sawamoto
    Walter Krauwinkel
    Marloes Schaddelee
    James Keirns
    Virginie Kerbusch
    Selina Moy
    John Meijer
    Donna Kowalski
    Richard Morton
    Kenneth Lasseter
    Dennis Riff
    Viera Kupčová
    Marcel van Gelderen
    [J]. Clinical Drug Investigation, 2013, 33 : 11 - 23
  • [9] Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Saxagliptin
    David Boulton
    Li Li
    Ernst U. Frevert
    Angela Tang
    Lorna Castaneda
    Nimish N. Vachharajani
    David M. Kornhauser
    Chirag G. Patel
    [J]. Clinical Pharmacokinetics, 2011, 50 : 253 - 265
  • [10] Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole
    Mallikaarjun, Suresh
    Shoaf, Susan E.
    Boulton, David W.
    Bramer, Steven L.
    [J]. CLINICAL PHARMACOKINETICS, 2008, 47 (08) : 533 - 542